Menu
Back to Journals » Therapeutics and Clinical Risk Management » Volume 13
Original Research
Ruxolitinib in myelofibrosis: to be or not to be an immune disruptor
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 16,016 | Dovepress* | 11,968+ | 1,857 | 13,825 | |
| PubMed Central* | 4,048 | 1,035 | 5,083 | ||
| Totals | 16,016 | 2,892 | 18,908 | ||
| *Since 13 February 2017 | |||||
View citations on PubMed Central and Google Scholar